{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:44:18Z","timestamp":1793659458905,"version":"4.5.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-integrin \u03b1v\u03b26 IgG autoantibodies showed good sensitivity and optimal specificity in ulcerative colitis (UC) compared to controls. We aim at confirming the diagnostic accuracy of anti-integrin \u03b1v\u03b26 autoantibodies in an Italian multicentric cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational multicentric study included adult and pediatric patients with inflammatory bowel disease and controls. Data on demographics, disease extension, partial Mayo score, fecal calprotectin, endoscopic Mayo score, and the time to the composite outcome including hospitalization or colectomy were collected. A new commercial ELISA kit was used to measure anti-integrin \u03b1v\u03b26 in the serum of the enrolled patients. Receiver operating curve (ROC) was used to identify the optimal cutoff to discriminate UC cases from other patients. Kaplan\u2013Meier curves and log-rank test were used to analyze the composite outcome hospitalization and need of colectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 228 patients were enrolled, including 36 controls (13 healthy donors and 24 diseased controls), 34 irritable bowel syndrome (IBS) patients, 50 Crohn\u2019s disease (CD) patients, and 107 UC patients. The UC patients presented higher values of anti-integrin \u03b1v\u03b26 IgG compared to CD, IBS, and controls (Kruskal\u2013Wallis test and\n                      <jats:italic>post-hoc<\/jats:italic>\n                      Holm\u2019s correction:\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). The ROC of anti-integrin \u03b1v\u03b26 IgG performed optimally with an area under the curve of 0.93. The optimal cutoff to distinguish UC from controls was 1.68 U\/mL, with a sensitivity of 87.9% and a specificity of 86.8% compared to non-UC patients with a specificity of 94.4% to non-IBD and 76% to CD, with very similar values to a recent multicentric study. A higher threshold up to 13 U\/mL may be useful to make a differential diagnosis between UC and CD with a specificity of 90%. Anti-integrin \u03b1v\u03b26 did not correlate with clinical disease activity but weakly with fecal calprotectin (\n                      <jats:italic>R<\/jats:italic>\n                      = 0.28,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.36) and moderately with endoscopic disease activity reported at the last colonoscopy (\n                      <jats:italic>R<\/jats:italic>\n                      = 0.60,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.03). Despite the low number of events, the log-rank test showed the potential predictive performance of high levels of anti-integrin \u03b1v\u03b26 IgG (i.e., &amp;gt;17 U\/mL) for the composite outcome (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study validates a new anti-integrin \u03b1v\u03b26 ELISA kit and confirms its high diagnostic accuracy in UC also in a European population, with particular utility in the differential diagnosis of specific forms of IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1641329","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:28:38Z","timestamp":1755754118000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Antibodies against integrin \u03b1v\u03b26 have high diagnostic accuracy for ulcerative colitis"],"prefix":"10.3389","volume":"16","author":[{"given":"Patrick","family":"Bez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Scapolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Giuseppe","family":"Ribaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Caviglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Trucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Frara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ascolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Campigotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Benvenuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Martelossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"De Lucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Faggin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Rattazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilde","family":"Manetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Mengozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Antico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: A review","volume":"330","author":"Gros","year":"2023","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohn\u2019s Colitis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756284819865153","article-title":"Endoscopy in inflammatory bowel disease: from guidelines to real life","volume":"12","author":"Negreanu","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diagnostics13182931","article-title":"Biomarkers in IBD: what to utilize for the diagnosis","volume":"13","author":"D\u2019Inc\u00e0","year":"2023","journal-title":"Diagnostics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1053\/j.gastro.2021.02.019","article-title":"Identification of an anti-integrin avb6 autoantibody in patients","volume":"160","author":"Kuwada","year":"2021","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071881","article-title":"Measurement of serum igG anti-integrin \u03b1 v \u03b2 6 autoantibodies is a promising tool in the diagnosis of ulcerative colitis","volume":"11","author":"Rydell","year":"2022","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-022-01680-y","article-title":"Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity","volume":"28","author":"Uzzan","year":"2022","journal-title":"Nat Portf"},{"key":"B9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.dld.2023.06.024","article-title":"Diagnostic value of anti-integrin \u03b1 v \u03b2 6 antibodies in ulcerative colitis","volume":"56","author":"Marafini","year":"2024","journal-title":"Dig Liver Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.12.042","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies are a novel biomarker that antedate ulcerative colitis","volume":"164","author":"Livanos","year":"2023","journal-title":"Gastroenterology"},{"key":"B11","volume-title":"R: A Language and Environment for Statistical Computing","year":"2023"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an opensource package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinf"},{"key":"B13","unstructured":"Therneau\n              TM\n            \n          \n          A Package for Survival Analysis in R\n          \n          2024"},{"key":"B14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00535-024-02176-x","article-title":"Anti-integrin \u03b1v\u03b26 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study","volume":"60","author":"Okabe","year":"2024","journal-title":"J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1053\/j.gastro.2022.06.026","article-title":"Anti\u2013integrin \u03b1v\u03b26 antibody as a diagnostic marker for pediatric patients with ulcerative colitis","volume":"163","author":"Muramoto","year":"2022","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf062","article-title":"Anti-integrin \u03b1v\u03b26 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype","volume":"19","author":"Pertsinidou","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02647-1","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis","volume":"130","author":"Yokode","year":"2024","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-02006-6","article-title":"Anti-integrin a v b 6 autoantibodies in patients with primary sclerosing cholangitis","volume":"58","author":"Yoshida","year":"2023","journal-title":"J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae131","article-title":"Integrin \u03b1V\u03b26: autoantigen and driver of epithelial remodeling in colon and bile ducts in primary sclerosing cholangitis and inflammatory bowel disease","volume":"19","author":"Roth","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.10.005","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies are increased in primary sclerosing cholangitis patients with concomitant inflammatory bowel disease and correlate with liver disease severity","volume":"23","author":"Bloemen","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.108.6.2241","article-title":"Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling","volume":"108","author":"Breuss","year":"1995","journal-title":"J Cell Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021873","article-title":"TGF- \u03b2 and the TGF-\u03b2 family: Context-dependent roles in cell and tissue physiology","volume":"8","author":"Morikawa","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000542","article-title":"The TGF-\u03b2\/smad system in IBD pathogenesis","volume":"21","author":"Sedda","year":"2015","journal-title":"Inflammation Bowel Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/15353702231151959","article-title":"TGF-\u03b2 receptor I inhibitor may restrict the induction of EMT in inflamed intestinal epithelial cells","volume":"248","author":"Ghorbaninejad","year":"2023","journal-title":"Exp Biol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240546","article-title":"Human ITGAV variants are associated with immune dysregulation, brain abnormalities, and colitis","volume":"221","author":"Ghasempour","year":"2024","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319015","article-title":"\u03b2 6 integrinosis: a new lethal autosomal recessive ITGB6 disorder leading to impaired conformational transitions of the \u03b1 V \u03b2 6 integrin receptor","volume":"69","author":"Weil","year":"2020","journal-title":"Gut"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2020.10.002","article-title":"Targeting B cells for inflammatory bowel disease treatment: back to the future","volume":"55","author":"Castro-Dopico","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.225482","article-title":"Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis","volume":"60","author":"Leiper","year":"2011","journal-title":"Gut"},{"key":"B29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/00365521.2020.1854847","article-title":"Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018","volume":"56","author":"Kristj\u00e1nsson","year":"2021","journal-title":"Scand J Gastroenterol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1641329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:28:41Z","timestamp":1755754121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1641329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1641329"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1641329","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"article-number":"1641329"}}